Sanofi Pasteur has agreed to collaborate with Oswaldo Cruz Foundation by means of its Immuno-biological Technology Institute, Bio-Manguinhos / Fiocruz and the Walter Reed Army Institute of Research (WRAIR) on Zika vaccine research.

WRAIR is a US Department of Defence Laboratory.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

WRAIR and Sanofi Pasteur previously signed a cooperative research and development agreement (CRADA) to conduct research and development of a Zika vaccine using the former’s inactivated-virus vaccine (ZPIV) technology.

Under the collaboration, Fiocruz, WRAIR and Sanofi Pasteur will combine their expertise in the fight against the virus.

"We have a common goal of developing a vaccine to prevent this emerging disease threat imposed by the Zika virus."

According to the CRADA, WRAIR will provide its ZPIV candidate to Sanofi Pasteur to produce clinical material in compliance with existing good manufacturing practices (GMP) to support testing during Phase II.

Along with the US National Institute for Allergy and Infectious Diseases (NIAID), WRAIR will sponsor and support a series of Phase I trials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

At present, Sanofi Pasteur is creating a clinical development and regulatory strategy while WRAIR and NIAID are conducting the Phase I ZPIV trials.

The collaboration will see process development, vaccine characterisation, epidemiological studies, pre-clinical and clinical evaluation of a vaccine, as well as clinical assay optimisation.

Sanofi Pasteur R&D vice-president John Shiver said: “It only makes sense for the pursuit of public health that we combine our expertise and resources on Zika with Fiocruz, which is ideally based in Brazil where the heart of the current Zika experience lies.

“We have a common goal of developing a vaccine to prevent this emerging disease threat imposed by the Zika virus.”

Sanofi Pasteur provides several vaccines against flaviviruses, such as yellow fever, dengue, and Japanese encephalitis.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now